



28th July, 2011

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001.

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067. INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

Dear Sir,

Re: Clause 41
Scrip Code: BSE – AJANTAPH 532331
NSE – AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Unaudited Financial Results for the first quarter ended 30th June, 2011 duly signed by the Managing Director. These results were approved by the Board of Directors at their Meeting held on Thursday, 28th July, 2011.

We are also enclosing a copy of the Press Release to be published in newspapers.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**

NIKHIL BHATT
G.M. - Legal &
Company Secretary

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Stand Alone Financial Results for the quarter ended 30th June, 2011

Particulars			₹ in Lacs
	3 months ended		Year Ended
	30/06/2011	30/06/2010	31/03/2011
	Unaudited		Audited
1. Net Sales/Income from Operations	12,730.77	9,828.67	45,714.56
2. Expenditure			
a. (Increase)/decrease in stock in trade and work in progress	(343.63)	(934.88)	537.37
b. Consumption of raw & packing materials	4,071.67	3,632.51	14,319.53
c. Purchase of traded goods	447.38	463.13	2,396.01
d. Employees cost	1,809.03	1,338.20	5,909.93
e. Depreciation & Amortisation	664.30	512.14	2,378.80
f. Research & Development Expenses	995.84	532.37	2,488.37
g. Other expenditure	3,622.31	3,011.63	11,108.47
h. Total	11,266.90	8,555.10	39,138.48
3. Profit from operations before Other Income, Interest & Exceptional Items	1,463.87	1,273.57	6,576.08
4. Other Income	177.15	20.52	164.96
5. Profit before Interest & Exceptional items	1,641.02	1,294.09	6,741.04
6. Interest	284.95	435.11	1,565.82
7. Profit after Interest but before Exceptional Items	1,356.07	858.98	5,175.22
8. Exceptional items	-	-	-
9. Profit from Ordinary Activities before tax	1,356.07	858.98	5,175.22
10. Tax Expense	103.00	161.10	530.68
11. Net Profit from Ordinary Activities after tax	1,253.07	697.88	4,644.54
12. Extraordinary items (net of tax expense)	-	-	-
13. Net Profit for the period	1,253.07	697.88	4,644.54
14. Paid-up Equity Share Capital (Face value of ₹10/- each)	1179.61	1179.61	1,179.61
15. Reserve excluding Revaluation Reserve	NA	NA	20,375.21
16. Earnings Per Share (EPS) Basic and diluted (not annualised) - ₹	10.70	5.96	39.67
17. Public Shareholding			
- Number of shares	3,884,879	3,884,879	3,884,879
- Percentage of shareholding	33.18%	33.18%	33.18%
18. Promoters and promoter group shareholding			
a) Pledged/Encumbered			
- Number of shares	200,000	200,000	200,000
- Percentage of total promoter's holding	2.56%	2.56%	2.56%
- Percentage of total share capital of company	1.71%	1.71%	1.71%
b) Non-encumbered			
- Number of shares	7,623,621	7,623,621	7,623,621
- Percentage of total promoter's holding	97.44%	97.44%	97.44%
- Percentage of total share capital of company	65.11%	65.11%	65.11%

Notes :

- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 28th July, 2011.
- Statutory Auditors have carried out Limited Review of the above results.
- The company has one segment of activity namely, pharmaceuticals.
- Investor's Complaints status - Opening - 0, Received - 13, Resolved - 13, Closing - 0.
- Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 28th July, 2011

COMPANY CONTACT:

Ajanta House,
Charkop, Kandivli (West),
Mumbai – 400 067
+91 22 66061000
www.ajantapharma.com

INVESTOR CONTACTS:

Nikhil Bhatt
Company Secretary
+91 22 66061203
nikhil.bhatt@ajantapharma.com

Press Release**Ajanta Pharma Net Profit up 80%**

Mumbai – (July 28, 2011) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has posted 80% increase in net profit for the first quarter of FY 2011-12. The Profit after Tax stood at Rs.12.53crores (Rs.6.98crores) for the quarter ended June 30, 2011. Net sales for the quarter ended June 30, 2011 stood at Rs.127.31crores (Rs.98.29crores), an excellent growth of 30% over same period of previous year.

“It is indeed a great pleasure to inform you that we have received the approval for our first product (ANDA) in USA recently. With this approval, Ajanta Pharma now joins the list of select few companies from India to have the product approved in world’s largest pharmaceutical market of USA.” said Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma Limited.

Commenting on results, he said “We are pleased with our Q1 performance. It is the result of our efforts and strategy to build a robust business model which delivers consistent results”. For last 10 years, company has posted CAGR 23% in sales and 42% in net profit.

About Ajanta pharma

Ajanta Pharma is a speciality pharmaceutical formulation company, having leading brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of the company’s products are first of its kind and are leading in their sub therapeutic segments. Company exports its products to more than 25 countries and established strong brand equity in these markets.

Ajanta Pharma has its State of the Art R&D centre located at Kandivali Mumbai, with more than 200 scientists working for formulation development. The company has world class manufacturing facilities - four located in India and one at Mauritius. One of the manufacturing facilities at Aurangabad is approved by US FDA and World health organisation (WHO), apart from having the approval from FDA of many other countries.

